|1.||Babu, Y S: 9 articles (04/2012 - 09/2000)|
|2.||Ison, Michael G: 8 articles (01/2015 - 03/2011)|
|3.||Boivin, Guy: 7 articles (12/2015 - 06/2002)|
|4.||Sidwell, R W: 7 articles (09/2003 - 03/2001)|
|5.||Abed, Yacine: 6 articles (12/2015 - 01/2006)|
|6.||Kitano, Mitsutaka: 6 articles (05/2015 - 11/2011)|
|7.||Kohno, Shigeru: 6 articles (01/2015 - 11/2010)|
|8.||Smee, Donald F: 6 articles (06/2014 - 05/2002)|
|9.||Smee, D F: 6 articles (09/2003 - 03/2001)|
|10.||Hurt, Aeron C: 5 articles (05/2015 - 04/2008)|
|1.||Human Influenza (Influenza)
06/01/2002 - "In mice infected with influenza A or B viruses, oral treatment with peramivir was highly effective in preventing death, signs of the disease and in lowering lung virus titres. "
09/01/2001 - "Viral challenge doses of influenza A/Shangdong/09/93 (H3N2) virus ranging from the LD(70) to the LD(100) did not affect the marked antiviral efficacy of 12.5 mg/kg of RWJ-270201 administered p.o. "
12/29/2001 - "Based on the high selectivity and efficacy of RWJ-270201 against both type A and B influenza strains in preclinical studies as well as murine pharmacodynamic studies supporting the potential for once-daily administration, clinical trials were initiated in order to determine the tolerability and antiviral activity of RWJ-270201 in humans. "
08/01/2012 - "These findings suggested that a single IV administration of peramivir had good potential for the treatment of equine influenza, and may help to limit the spread of the disease in the horse population."
05/01/2013 - "These data indicated that repeated administration of peramivir was effective in promoting the survival and reducing virus replication in immunosuppressed mice infected with influenza A (H1N1) 2009 virus."
01/01/2012 - "Peramivir exposure in children was within the range of levels within which the efficacy and safety was confirmed in adults, and it is considered that peramivir is clinically and virologically effective and safe in children with pH1N1 virus infection."
11/01/2011 - "We evaluated the efficacy of a single intravenous dose peramivir for treatment of influenza B virus infection in ferrets and cynomolgus macaques in the present study. "
04/01/2011 - "These data demonstrate efficacy of parenterally administered peramivir against the recently isolated pandemic influenza virus in murine infection models."
09/01/2014 - "The purpose of this study was to investigate the relationship between pharmacokinetic (PK) parameters of intravenous (IV) peramivir and in vivo antiviral activity pharmacodynamic (PD) outcomes in a mouse model of influenza virus infection. "
05/01/2015 - "Peramivir was intravenously administered after the viral infection. "
|3.||Body Weight (Weight, Body)
04/01/2012 - "Improved body weight relative to either compound alone was evident using 0.25, 0.5, and 1 mg/kg/d of peramivir. "
03/01/2015 - "Serum, nasal swab, or aspiration samples were collected from 28 patients treated with 10 mg/kg body weight peramivir. "
05/01/2013 - "Repeated administration of peramivir (40 mg/kg of body weight once a day, given intravenously for 20 days), starting at 1 h p.i., significantly reduced mortality, body weight loss, viral titers, and cytokine production in infected mice compared with results for administration of vehicle (P < 0.01). "
08/01/2012 - "Regimens consisted of single (90 mg/kg of body weight) or multiple (45 mg/kg daily for 5 days) IM peramivir doses that were initiated 24 h or 48 h postinfection (p.i.). "
11/01/2011 - "A single dose of peramivir (60 mg/kg of body weight) given to ferrets on 1 day postinfection with influenza B virus significantly reduced median area under the curve (AUC) virus titers (peramivir, 8.3 log(10) 50% tissue culture infective doses [TCID(50)s] · day/ml; control, 10.7 log(10) TCID(50)s · day/ml; P < 0.0001). "
|4.||Influenza in Birds (Avian Flu)
08/01/2014 - "Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques."
12/01/2015 - "Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model."
10/01/2001 - "RWJ-270201 inhibited the replication of avian influenza viruses of both Eurasian and American lineages in MDCK cells (50% effective concentration, 0.5 to 11.8 microM). "
04/25/2008 - "The post-exposure therapeutic efficacy of injectable peramivir against highly pathogenic avian influenza type A H5N1 was evaluated in mice and in ferrets. "
12/01/2015 - "This study demonstrates the antiviral activity of peramivir in a mouse model of H7N9 avian influenza virus infection. "
|5.||Critical Illness (Critically Ill)
01/01/2012 - "The high mortality could be due to the pre-existing clinical severity of cases prior to request for peramivir, but also raises questions about peramivir safety and effectiveness in hospitalized and critically ill patients. "
10/01/2015 - "The clinical efficacy of peramivir in the treatment of severe seasonal influenza in critically ill patients admitted to an intensive care unit (ICU) is not well established. "
07/01/2012 - "Many peramivir recipients under the EUA were critically ill and at risk for influenza-related complications. "
10/01/2010 - "Two critically ill women with 2009 H1N1 influenza A treated with compassionate-use intravenous peramivir administered as a daily infusion of 600 mg over 30 minutes while receiving continuous venovenous hemodiafiltration (CVVHDF), a form of CRRT. "
10/01/2015 - "The aim of this study was to compare the clinical efficacy of peramivir with that of oseltamivir in such critically ill patients. "
|5.||Antiviral Agents (Antivirals)
|9.||caprylic acid (octanoate)